A prospective study of a Multi-Cancer Early Detection Blood Test (ESMO 2022)

• Cohort: >6,600 adults ages 50-79y with and without additional cancer risk factors from 7 U.S. sites - Intended use population

• Study Design: Prospective, interventional, return-of-results study to evaluate the clinical implementation and impact of an MCED test on cancer diagnostic and care pathways.

• Key Outcomes: MCED screening was safely implemented, key performance metrics were validated and participant levels of anxiety, distress and uncertainty were low. The results from PATHFINDER supported broad screening use of Galleri.